400
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Regeneron's recently active trials. Comparator arms are excluded.
- Cemiplimab13 trials
- REGN750810 trials
- Linvoseltamab9 trials
- cemiplimab6 trials
- REGN99335 trials
- Odronextamab5 trials
Upcoming readouts
Next primary completion dates among Regeneron's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Dec 2026ASCEND-QW: A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who …Phase 2
- Feb 2027ROXI-ATLAS: Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationPhase 2
- Feb 2027ROXI-APEX: REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in …Phase 3
- Mar 2027A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Adva…Phase 3
- May 2027ROXI-ASPEN: REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthro…Phase 3
- Aug 2027KYRIAD: A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic AmenorrheaPhase 2
Top therapeutic areas
Conditions studied most often across Regeneron's recently active trials.
- Melanoma4 trials
- Atrial Fibrillation (AF)3 trials
- Venous Thromboembolism (VTE)3 trials
- Generalized Lipodystrophy3 trials
- Overweight or Obesity3 trials
- Ovarian Cancer2 trials
Regeneron pipeline by phase
The main study drugs across 110 active trials Regeneron leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 310 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| REGN7508 | 9 | 8 | Feb 2027 est. | NCT07697599 · NCT07626411 · NCT07493304 |
| Cemiplimab | 8 | 2 | May 2027 est. | NCT06585410 · NCT03969004 · NCT07808515 |
| Odronextamab | 7 | 4 | Feb 2028 est. | NCT06230224 · NCT06149286 · NCT06097364 |
| Fianlimab | 6 | 1 | Mar 2027 est. | NCT06246916 · NCT05608291 · NCT05352672 |
| Mibavademab | 3 | 3 | Jun 2027 est. | NCT07220785 · NCT07220772 · NCT07235917 |
| Garetosmab | 2 | — | Dec 2028 est. | NCT07559513 · NCT05394116 |
| Aflibercept 8 mg | 1 | — | — | NCT06491914 |
| Pozelimab + Cemdisiran | 1 | — | — | NCT05070858 |
| Ravulizumab | 1 | — | Oct 2026 est. | NCT05133531 |
| REGN-2Cat | 1 | 1 | May 2029 est. | NCT07675811 |
Phase 214 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Ubamatamab | 3 | 3 | May 2027 est. | NCT07154290 · NCT06787612 · NCT03564340 |
| ALN-ANG3 | 2 | 1 | Dec 2026 est. | NCT07271186 · NCT06452771 |
| ALN-CIDEB | 2 | 1 | May 2027 est. | NCT07631637 · NCT06836609 |
| ALN-PNP | 2 | 2 | Aug 2027 est. | NCT07527910 · NCT05648214 |
| Olatorepatide | 2 | 1 | Nov 2026 est. | NCT07685808 · NCT07431086 |
| Alirocumab | 1 | 1 | Dec 2026 est. | NCT07477704 |
| ALN-HSD | 1 | 1 | Apr 2028 est. | NCT05519475 |
| BNT116 | 1 | — | Jan 2028 est. | NCT05557591 |
| FDC fianlimab+cemiplimab | 1 | 1 | Jun 2028 est. | NCT06769698 |
| Fianlimab+cemiplimab | 1 | — | Oct 2029 est. | NCT06848088 |
| Fixed Dose Combination (FDC) cemiplimab+fianlimab | 1 | — | Nov 2026 est. | NCT06190951 |
| REGN13335 | 1 | 1 | Feb 2028 est. | NCT07318597 |
| REGN7999 | 1 | — | Dec 2026 est. | NCT06421636 |
| Trevogrumab-Part A | 1 | — | — | NCT06299098 |
Phase 123 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Vonsetamig | 2 | 1 | Nov 2027 est. | NCT06975787 · NCT05092347 |
| 89Zr˗DFO˗REGN5054 | 1 | 1 | Jan 2027 est. | NCT05259709 |
| ALN-CFB | 1 | 1 | Nov 2029 est. | NCT07187401 |
| ALN-F1202 | 1 | — | — | NCT06669234 |
| ALN-SNCA | 1 | 1 | Jun 2029 est. | NCT07216066 |
| ALN-SOD | 1 | 1 | Mar 2032 est. | NCT06351592 |
| BPX-601 | 1 | 1 | Feb 2030 est. | NCT07543055 |
| DB-OTO | 1 | 1 | Feb 2029 est. | NCT05788536 |
| REGN10597 | 1 | 1 | Feb 2030 est. | NCT06413680 |
| REGN15505 | 1 | 1 | Oct 2030 est. | NCT07594106 |
| REGN17235 | 1 | — | May 2031 est. | NCT07753148 |
| REGN17372+Linvoseltamab | 1 | 1 | Sept 2033 est. | NCT07455851 |
| REGN20423 | 1 | 1 | Jun 2028 est. | NCT07527923 |
| REGN20934 | 1 | 1 | Feb 2027 est. | NCT07594093 |
| REGN22044 | 1 | 1 | Feb 2027 est. | NCT07526116 |
| REGN22530 | 1 | — | Jul 2029 est. | NCT07675824 |
| REGN4336 | 1 | 1 | Mar 2030 est. | NCT05125016 |
| REGN5093 | 1 | — | Jul 2027 est. | NCT04077099 |
| REGN5668 | 1 | 1 | Mar 2027 est. | NCT04590326 |
| REGN5678 | 1 | 1 | Nov 2027 est. | NCT03972657 |
| REGN7075 | 1 | — | Nov 2026 est. | NCT04626635 |
| REGN9933 | 1 | — | Mar 2027 est. | NCT07759167 |
| REGV131 | 1 | 1 | Aug 2034 est. | NCT06379789 |
Phase 43 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Linvoseltamab | 12 | 10 | Aug 2027 est. | NCT07609940 · NCT07393282 · NCT07222761 |
| Dupilumab | 9 | 2 | Oct 2026 est. | NCT07587658 · NCT06572228 · NCT07112378 |
| Pozelimab | 5 | 5 | Jul 2028 est. | NCT07142343 · NCT07154745 · NCT06541704 |
Derived from 110 active trials Regeneron leads; 110 name an intervention, folding into 50 phased drugs. 1 intervention carries no registry phase (observational studies, tests and devices) and is not shown. This is ComplyRx's reading of the registry, not Regeneron's own pipeline disclosure.
Regeneron trials
The 50 most significant of Regeneron's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USNCT07431086Olatorepatide | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 120 est. | 13 Nov 2026 |
| COMBINE-EGFR-1A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersNCT04626635REGN7075 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 548 est. | 13 Nov 2026 |
| FERVENT-1A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the BodyNCT06421636REGN7999 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 19 est. | 3 Dec 2026 |
| ASCEND-QWA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaNCT07477704Alirocumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 420 est. | 29 Dec 2026 |
| A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy AdultsNCT07526116REGN22044 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 88 est. | 8 Feb 2027 |
| ROXI-ATLASSafety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationNCT07175428REGN7508 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 1,200 est. | 9 Feb 2027 |
| ROXI-APEXREGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsNCT07015905REGN7508 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 2,000 est. | 20 Feb 2027 |
| Safety and Drug Concentrations of REGN20934 in Adults With Overweight or ObesityNCT07594093REGN20934 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 90 est. | 22 Feb 2027 |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)NCT06246916fianlimab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 560 est. | 22 Mar 2027 |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabNCT04590326REGN5668 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 612 est. | 25 Mar 2027 |
| Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on HemodialysisNCT07759167REGN9933 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 36 est. | 25 Mar 2027 |
| AROMAStudy Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)NCT04959448DUPIXENT® | — | Locked · track to reveal | OngoingActive, not recruiting | 717 est. | 25 Mar 2027 |
| Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) ParticipantsNCT06269133REGN2810 | — | Not yet scored | OngoingActive, not recruiting | 1,000 est. | 31 Mar 2027 |
| Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersNCT03564340Ubamatamab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 890 est. | 10 May 2027 |
| A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)NCT06836609ALN-CIDEB | Phase 1 | Locked · track to reveal | OngoingRecruiting | 132 est. | 15 May 2027 |
| ROXI-ASPENREGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsNCT07213778REGN7508 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 2,000 est. | 17 May 2027 |
| A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)NCT06465329Cemiplimab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 120 est. | 20 May 2027 |
| An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney TransplantNCT05106387Noninterventional | — | Not yet scored | OngoingRecruiting | 20 est. | 14 Jun 2027 |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung CancerNCT04077099REGN5093 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 95 est. | 6 Jul 2027 |
| KYRIADA Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic AmenorrheaNCT07235917Mibavademab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 34 est. | 20 Aug 2027 |
| Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food AllergyNCT06369467linvoseltamab | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 6 est. | 31 Aug 2027 |
| A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT05785767fianlimab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 149 est. | 28 Sept 2027 |
| POPLINAdult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)NCT07609940Linvoseltamab | Phase 4 | Locked · track to reveal | OngoingRecruiting | 30 est. | 11 Oct 2027 |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsNCT03972657REGN5678 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 345 est. | 15 Nov 2027 |
| A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)NCT05092347Vonsetamig | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 43 est. | 22 Nov 2027 |
| A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch AllergyNCT07710846Noninterventional | — | Not yet scored | OngoingNot yet recruiting | 1,500 est. | 10 Jan 2028 |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesNCT07685808Olatorepatide | Phase 2 | Not yet scored | OngoingRecruiting | 360 est. | 21 Jan 2028 |
| OLYMPIA-1A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaNCT06091254Odronextamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 822 est. | 7 Feb 2028 |
| ILLUMINATEStudy of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)NCT07318597REGN13335 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 99 est. | 27 Feb 2028 |
| A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsNCT05137054Linvoseltamab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 317 est. | 25 Mar 2028 |
| OLYMPIA-3A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaNCT06091865Odronextamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 904 est. | 30 Mar 2028 |
| NASHGEN-2A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This ConditionNCT05519475ALN-HSD | Phase 2 | Locked · track to reveal | OngoingRecruiting | 120 est. | 27 Apr 2028 |
| LAGOEfficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized LipodystrophyNCT07220785Mibavademab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 28 est. | 19 May 2028 |
| A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06769698FDC fianlimab+cemiplimab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 120 est. | 4 Jun 2028 |
| EoE-TOTsA Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisNCT07112378dupilumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 20 est. | 19 Jun 2028 |
| AURA-ADFirst-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisNCT07527923REGN20423 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 144 est. | 23 Jun 2028 |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerNCT06787612Ubamatamab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 297 est. | 30 Jun 2028 |
| VIENNAIntravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult ParticipantsNCT07230834Pozelimab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 54 est. | 3 Jul 2028 |
| SIENNAA Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyNCT06541704Pozelimab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 975 est. | 31 Jul 2028 |
| LINKER-AL2A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)NCT06292780Linvoseltamab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 220 est. | 20 Aug 2028 |
| ACCESS-EXTA Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksNCT05744921Pozelimab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 202 est. | 10 Oct 2028 |
| ANCHOR-POCStudy to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney DiseaseNCT07271186ALN-ANG3 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 195 est. | 13 Oct 2028 |
| CEMI-LUNGAn Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeNCT05363319Cemiplimab | — | Not yet scored | OngoingRecruiting | 500 est. | 30 Oct 2028 |
| OPTIMA-2A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)NCT07559513garetosmab | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 18 est. | 10 Dec 2028 |
| Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07631637ALN-CIDEB | Phase 2 | Not yet scored | OngoingNot yet recruiting | 150 est. | 6 Feb 2029 |
| CHORDA Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin MutationsNCT05788536DB-OTO | Phase 1 | Locked · track to reveal | OngoingRecruiting | 36 est. | 26 Feb 2029 |
| ROXI-INCLINEStroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitableNCT07430956REGN7508 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 2,628 est. | 28 Mar 2029 |
| LINKER-MM5A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)NCT07222761Linvoseltamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 915 est. | 21 May 2029 |
| A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat AllergyNCT07675811REGN-2Cat | Phase 3 | Not yet scored | OngoingRecruiting | 570 est. | 31 May 2029 |
| ROXI-PEAKVenous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)NCT07697599REGN7508 | Phase 3 | Not yet scored | OngoingNot yet recruiting | 1,908 est. | 25 Jun 2029 |